The company has received approval from Health Canada to conduct the CAN-PRIME Study, according to a Nov. 20 news release. This study aims to evaluate the safety of Neuralink’s implant and surgical robot while testing the effectiveness of its brain-computer interface (BCI).
The BCI is designed to enable individuals with quadriplegia to control external devices using their thoughts. The trial is open to Canadian residents with limited or no use of both hands due to ALS or cervical spinal cord injury.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
